Review Article
Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli
Table 2
Fosfomycin concentrations in plasma, urine, and prostate following a single 3 g oral dosea.
| | Parameter | Mean (±SD) | Median | Range |
| | Plasma | | | | | Time after dose (min) | 565 (149) | 578.5 | 385–995 | | Concentration (μg/mL) | 11.42 (7.60) | 10.84 | 2.29–40.38 | | Urine | | | | | Time after dose (min) | 581 (150) | 593 | 398–1020 | | Concentration (μg/mL) | 570.57 (418.40) | 434.86 | 47.99–1522.05 | | Prostate transition zone | | | | | Time after dose (min) | 598 (152) | 598 | 420–1025 | | Concentration (μg/g) | 8.30 (6.63) | 5.35 | 0.56–26.05 | | Prostate peripheral zone | | | | | Time after dose (min) | 608 (155) | 598 | 420–1067 | | Concentration (μg/g) | 4.42 (4.10) | 2.97 | 0.17–18.06 | | Prostate mean | | | | | Time after dose (min) | 602.87 (153.36) | 598 | 420–1046 | | Concentration (μg/g) | 6.50 (4.93) | 4.67 | 0.67–22.06 | | Prostate/plasma ratio | 0.67 (0.57) | 0.50 | 0.07–2.92 |
|
|
aData adapted from reference [ 9]; SD, standard deviation. |
